ALHEMO

GrowthmAb

concizumab

BLASubcutaneousInjectablePriority Review
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
9

Mechanism of Action

Tissue Factor Pathway Inhibitor Antagonists

Pharmacologic Class:

Tissue Factor Pathway Inhibitor Antagonist

Clinical Trials (5)

NCT06831734N/AEnrolling By Invitation

Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

Started May 2025
30 enrolled
Haemophilia A, Haemophilia B
NCT06285071N/AEnrolling By Invitation

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Started Aug 2024
23 enrolled
Haemophilia AHaemophilia B
NCT05135559Phase 3Active Not Recruiting

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

Started Mar 2022
153 enrolled
Haemophilia A and B With and Without Inhibitors
NCT04082429Phase 3Active Not Recruiting

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

Started Nov 2019
156 enrolled
Haemophilia A Without InhibitorsHaemophilia B Without Inhibitors
NCT04083781Phase 3Active Not Recruiting

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

Started Oct 2019
134 enrolled
Haemophilia A With InhibitorsHaemophilia B With Inhibitors